LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer

Core Insights - LeonaBio, Inc. has appointed Mark F. Kubik as Chief Business Officer to lead its business development strategy, focusing on licensing, partnership strategy, and corporate development initiatives [1][3] Company Overview - LeonaBio is a clinical-stage biopharmaceutical company based in Bothell, Washington, dedicated to developing novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS) [10] Leadership Appointment - Mark F. Kubik brings over 25 years of biopharma business development and corporate strategy experience, having previously served as a strategic consultant to LeonaBio [2][4] - His appointment is seen as pivotal for advancing the Phase 3 development of lasofoxifene for metastatic breast cancer and building a diversified pipeline in oncology and neurodegeneration [3] Strategic Vision - Mr. Kubik expressed excitement about joining LeonaBio at a critical juncture, emphasizing the urgency of advancing lasofoxifene as a therapeutic candidate for treatment-resistant metastatic breast cancer [3] - The company aims to expand its portfolio and explore strategic collaborations under his leadership [3] Inducement Stock Option - LeonaBio announced an equity inducement award to Mr. Kubik, granting him stock options to purchase 30,000 shares at an exercise price of $4.74, effective from February 1, 2026 [6][7] - The vesting schedule includes one-fourth of the shares vesting on the first anniversary and one forty-eighth each month thereafter, contingent on continued service [8] Educational Background - Mr. Kubik holds an MBA in Finance and a BA in Molecular, Cellular and Developmental Biology from the University of Colorado, Boulder, and has completed Executive Education in Negotiation and Influence Strategies at Stanford University [5]